Cockayne syndrome …

Arushi Gahlot Saini MD DM MNAMS

Neurogenetic Disorders

Updated 05.08.2026
Released 04.07.1995
Expires For CME 05.08.2029

Cockayne syndrome

Author: Arushi Gahlot Saini MD DM MNAMS

See Contributor Disclosures

Editor: Ganeshwaran H Mochida MD PhD

Cite this article

Cockayne syndrome

In This Article

Quick Link

Introduction

Overview

Cockayne syndrome is a rare, autosomal recessive, multisystem, progressive degenerative brain disease caused by pathogenic variations in the excision repair cross complementation group 8 (ERCC8; OMIM# 609412) and excision repair cross complementation group 6 (ERCC6; OMIM# 609413) leading to Cockayne syndrome type A (OMIM# 216400) and type B (OMIM# 133540), respectively. The features of Cockayne syndrome include cachectic dwarfism, cataracts, optic atrophy, intellectual disability, unusual facies and body habitus, hearing loss, a peculiar form of fine pigmentary retinitis without the typical spicules of retinitis pigmentosa, and some similarities to the condition progeria. The neurologic abnormalities observed in patients with Cockayne syndrome are often collectively referred to as Cockayne syndrome neurologic disease. The phenotypic spectrum of Cockayne syndrome has been divided into three clinical presentations.

Cockayne syndrome type I (“classic” form) is a moderate form that presents with growth and developmental abnormalities in the first 2 years of life. The prenatal period of growth is normal, and death occurs by the first or second decade of life.

Cockayne syndrome type II is more severe form in which major abnormalities are recognized at birth or in the early neonatal period, with little or no postnatal development. Death occurs by 5 years of age.

The term cerebro-oculo-facio-skeletal (COFS) syndrome and its synonym, Pena-Shokeir syndrome type II, have been used to refer to a heterogeneous group of disorders characterized by congenital neurogenic arthrogryposis (multiple joint contractures), microcephaly, microphthalmia, and cataracts. The original cases of COFS syndrome described by Pena and Shokeir in 1974 among native Canadian families from Manitoba harbor homozygous pathogenic variants in ERCC6. COFS syndrome is now regarded as an allelic and prenatal form of Cockayne syndrome, partly overlapping with Cockayne syndrome type II, and includes the most severe cases of the Cockayne syndrome phenotypic spectrum (69).

Cockayne syndrome type III is a milder or late-onset form that presents after 2 years of age, and growth and cognition are relatively better compared to other forms. Some very mild patients even reach a normal height and weight and a normal intellectual level but show late-onset cerebellar ataxia and secondary cognitive decline. This adult-onset subgroup of Cockayne syndrome is sometimes named Cockayne syndrome type IV and often represents a very difficult diagnostic challenge (40). Both Cockayne syndrome type III and type IV show purely neurodegenerative symptoms of the Cockayne syndrome spectrum.

A subset of patients presenting with mutations in one of several xeroderma pigmentosum genes, including ERCC3 (encodes XPB), ERCC2 (encodes XPD), ERCC4 (encodes XPF), ERCC5 (encodes XPG), and ERCC1 (DNA excision repair protein that works with ERCC4), also experience neurologic disease that is characteristic of Cockayne syndrome, along with the elevated risk of skin cancer observed in xeroderma pigmentosum. Such patients are classified as having xeroderma pigmentosum–Cockayne syndrome and belong to complementation group Cockayne syndrome type C.

Cockayne syndrome is extremely rare, with approximately 200 cases in the literature. In Europe, its annual incidence is estimated at one case per 200,000 births (91; 94). In a nationwide survey of Cockayne syndrome in Japan, the incidence was estimated to be 2.77 per million births (95% CI: 2.19–3.11), and the prevalence was approximately one in 2,500,000 (66). No race or sex predilection is reported for Cockayne syndrome; the male-to-female ratio is equal. Cockayne syndrome type 1 manifests in childhood, whereas type 2 has a worse prognosis and manifests at birth or in infancy. Death generally occurs by the age of 30 years, secondary to inanition or infection. Current management focuses on symptomatic therapy, although the possibility of gene therapy is under investigation.

Key points

	• Cockayne syndrome is an autosomal recessive multisystem disorder, predominantly characterized by neurologic and sensory impairment, cachectic dwarfism, and photosensitivity.
	• Based on the complementation groups, Cockayne syndrome is divided into types A, B, and C. The clinical features represent a spectrum of severity, and Cockayne syndrome is divided into clinical types I to III based on the features.
	• Clinically, the most typical form is known as Cockayne syndrome type I. A severe form seen at birth is known as Cockayne syndrome type II (also includes COFS). A much milder form is known as Cockayne syndrome type III, including the anecdotal adult-onset type IV). In addition, an entity known as xeroderma pigmentosum–Cockayne syndrome is recognized.
	• Diagnosis is made on clinical grounds and confirmed by molecular genetic testing. Molecular prenatal diagnosis of Cockayne syndrome has been successful. Carrier detection (50% chance of being an asymptomatic carrier) is available once the mutations have been identified in the proband.
	• Treatment consists of purely supportive care.
	• Cockayne syndrome is characterized by a deficiency in the transcription-couple DNA repair pathway caused by mutations mainly in the Cockayne syndrome group B gene (ERCC6 or CSB).

Historical note and terminology

Cockayne syndrome, or Cockayne-Neill-Dingwall syndrome, was first reported by English physician Edward Alfred Cockayne (1880–1956) in 1936 and re-described in 1946 in a brother and sister with dwarfism and retinal atrophy (26). He made a follow-up report in 1946, at which time he reported that the children were markedly different than at the first presentation (27). The features of the condition included the postnatal onset of dwarfism, cataracts, optic atrophy, mental retardation, unusual facies and body habitus, hearing loss, and a peculiar form of fine pigmentary retinitis without the typical spicules seen in retinitis pigmentosa. Neill and Dingwall later reported on another child and commented on some similarities to the condition of progeria (87), hence, the other name of the syndrome, “Neill-Dingwall syndrome.” Macdonald and colleagues reported three additional patients in a family (78). They saw a clear and sharp distinction between Cockayne syndrome and progeria, a point that has been clearly borne out by the discovery of the underlying pathogenesis in Cockayne syndrome.

The first step towards the development of experimental models of Cockayne syndrome was the in vitro culture of skin fibroblasts derived from patients with Cockayne syndrome in the 1970s. These fibroblasts were shown to be extremely sensitive to UV light (106; 08) and displayed a marked defect in the recovery of RNA synthesis after UV irradiation (71) due to a failure in the repair of transcriptionally active genes (127; 124). Subsequently, evaluation of post-UV RNA synthesis recovery in multinucleated cells obtained by the fusion of cells from different Cockayne syndrome donors led to the identification of three complementation groups (A, B, and C) (114; 71). In the 1990s, the genes corresponding to A and B were characterized and termed CSA and CSB, respectively. Group C identified by Lehmann corresponded to the xeroderma pigmentosum–Cockayne syndrome spectrum. CSB was originally termed ERCC6 (excision repair cross-complementation group 6) because it was found to complement the nucleotide excision repair (NER) defect in the complementation group 6 of rodent cell lines defective in excision repair (121). Subsequently, Troelstra demonstrated that ERCC6 gene expression could reverse UV sensitivity and rescue post-UV RNA synthesis in CSB but not in CSA (122). In 1995, the second gene ERCC8 encoding CSA protein was identified, which reversed the UV sensitivity of Cockayne syndrome cells from group A (47). Subsequently, it became clear that both genes interacted with each other and played critical roles in the transcription-coupled nucleotide excision repair (TC-NER) of damaged DNA (54). A main component for the NER pathway is transcription factor IIH (TFIIH), a multifunctional, 10-subunit protein complex with crucial roles in both transcription and NER. In transcription, TFIIH is a component of the pre-initiation complex and is important for promoter opening and the phosphorylation of RNA polymerase II (RNA Pol II). In NER, TFIIH binds to DNA after DNA damage is detected and, using its translocase and helicase subunits XPB and XPD, opens up the DNA and checks for the presence of DNA damage. This central activity leads to dual incision and removal of the DNA strand containing the damage, after which the resulting DNA gap is restored (115). This central function of TFIIH in NER is an active area of research, and pathogenic variations within subunits of the TFIIH complex have been linked to xeroderma pigmentosum, xeroderma pigmentosum combined with Cockayne syndrome, and trichothiodystrophy via its two NER sub-pathways: global genomic and transcription-coupled NER (49). Further, transcription-coupled NER selectively removes DNA lesions from the transcribed strand of active genes. It starts with lesion recognition by RNA Pol II and CSB, but efficient repair requires their removal. DNAJA2 is being recognized as a key mediator that promotes chaperone-mediated autophagy via HSC70 to degrade and clear CSB and RNA Pol II through the lysosomal receptor LAMP2A. Disruption of DNAJA2, HSC70, or LAMP2A impairs this process, highlighting their essential role in regulating TC-NER and maintaining genome stability (52; 134).

Clinical manifestations

Presentation and course

Cockayne syndrome is a genetic condition characterized by short stature, microcephaly, mental retardation, characteristic senile appearance, retinopathy, sensorineural hearing loss, and the development of a leukodystrophy that results from a defect in the repair mechanism of actively transcribed DNA (72). Formal clinical diagnostic criteria originally proposed for Cockayne syndrome type I (85) have been revised and extended in more recent publications (84; 67). Clinical diagnosis requires three major criteria (progressive growth failure, mental retardation, and microcephaly) together with two minor criteria from the following: cataracts or pigmentary retinopathy, sensorineural hearing loss, dental abnormalities, loss of subcutaneous fat, and skin photosensitivity. Diagnostic and severity scores for Cockayne syndrome have been proposed that facilitate early diagnosis and longitudinal evaluation of possible therapeutic interventions (110). Marked clinical heterogeneity may occur even among individuals carrying the same pathogenic variant. Patients harboring an identical truncating mutation in ERCC6 have been reported to exhibit three distinct phenotypic presentations, ranging from severe early-onset disease to milder forms, highlighting the influence of modifier genes and limiting the prognostic value of genotype alone (58). The following are important features.

Postnatal growth failure. Growth slows in the first year of life so that by early childhood, it is two standard deviations below the mean for weight and height (85). The profound dwarfing, failure of brain growth, cachexia, selectivity of tissue degeneration, and poor correlation between genotypes and phenotypes are not understood (98). Specific Cockayne syndrome growth charts have been proposed to monitor growth and nutrition in these patients (10). These studies show that individuals with Cockayne syndrome type I initially have normal growth parameters. Microcephaly occurs from 2 months, whereas onset of weight and height restrictions appear later, between 5 and 22 months. In Cockayne syndrome type II, growth parameters are already below standard references at birth or drop below the fifth percentile before 3 months. Microcephaly is the first parameter to show a delay, appearing around 2 months in Cockayne syndrome type I and at birth in Cockayne syndrome type II. Height and head circumference are more severely affected in Cockayne syndrome type II compared to type I, whereas weight curves are similar in patients with Cockayne syndrome types I and II (10).

Typical progeroid facies. The facial appearance of patients with Cockayne syndrome is distinctive as they grow older. A loss of subcutaneous periorbital fat of the face occurs as they mature, giving a wizened look. The eyes are sunken. The ears and nose are prominent. The ears are cupped and large, the nose long and angulated. The teeth are carious (26; 27; 87; 78; 85).

Photosensitivity. Because of the impaired ability to repair DNA damage resulting from ultraviolet exposure, the skin is extremely sensitive to sunlight, often burning even after a trivial exposure. This photosensitivity has been reported in three fourths of affected individuals (85). There may be secondary reaction by the skin to this photosensitivity, but there is no increase in skin malignancy. This stands in contrast to the related condition xeroderma pigmentosa. Other skin manifestations include dry, scaly skin and thin hair; diminished subcutaneous tissue; dry, scaly skin; and occasionally anhidrosis (85). Sonmez and colleagues reported six patients with Cockayne syndrome type B without photosensitivity. They are all from the same inbred family and exhibit variable clinical features, including progressive encephalopathy, intracranial calcification and white-matter lesions, dwarfism without growth hormone deficiency, senile appearance, mental and motor retardation, atrophy of subcutaneous fat tissue, severe pectus carinatus, and spasticity. Clinical photosensitivity was not observed in any patient. The onset of the disease was between three and six months of age. Molecular genetic analyses in the family established linkage to ERCC6, confirming the clinical diagnosis, Cockayne syndrome type B (109). Tinsa and colleagues described a rare case of Cockayne syndrome that started in early infancy and presented with no photosensitivity (118).

Eye involvement. Eye involvement includes retinopathy, enophthalmos, strabismus, amblyopia, and cataract (119). The pigmentary changes in the retina are fine, involve the periphery, and are progressive. Studies utilizing electroretinogram and retinography in older patients show diffuse pigmentary retinopathy and macular atrophy (34). Bone spicules have been seen in older patients. Retinal dystrophy is seen in 60% of patients (85). Cockayne's original patients had cataracts, a feature seen in only 15% of patients (119). Visual acuity may be preserved in spite of significant retinal changes and optic atrophy. Other ophthalmological involvements have been optic atrophy, nystagmus, corneal lesions, band keratopathy, recurrent erosions, and poor pupillary response to dilating agents (119).

Sensorineural hearing loss. Sensorineural hearing loss occurs in over half of the individuals, with involvement ranging from mild to severe (85). Cellular degeneration of multiple components of the temporal bone has been reported (44). As with other features in this condition, the onset may be delayed and not apparent until late childhood or adolescence.

Neurocognitive impairment. The coexistence of impairment of hearing and vision make cognitive ability difficult to evaluate but, with few exceptions, individuals are moderately to severely impaired. Milestones in the first year of life may be near normal, but later, delays become evident. Many speak, although language is often reported as immature. There may be surprisingly good social interaction and ability to make interpersonal contact (78). Symptoms of neurocognitive and neuropsychiatric decline are very common in adult cohorts of Cockayne syndrome, suggesting that these individuals are at risk of developing neurocognitive and neuropsychiatric decline, with symptoms related to but not specific to dementia (97).

Motor impairment. The development of leukodystrophy results in progressive neurologic deterioration. Often spasticity, ataxia, or choreoathetosis are experienced. Tremor may be prominent and may respond to levodopa (103). The demyelination is both central and peripheral, with the peripheral neuropathy demonstrated by muscle weakness and wasting (85). Young patients may manifest epilepsy (41). Axonal sensorimotor polyneuropathy may be a prominent feature in some patients with ERCC6-related Cockayne syndrome. A 2025 report described a patient with Cockayne syndrome type B caused by a de novo ERCC6 mutation presenting with clinically significant axonal sensorimotor neuropathy, further expanding the phenotypic spectrum of peripheral nervous system involvement (37).

Contractures of the large joints. Contractures of the large joints result in a stooped posture with splayed legs. A bow-legged or horse-riding stance and a peculiar gait can be seen in those who walk (78). The limbs themselves are long, with large hands and feet, and may be held in flexion (41). Kyphoscoliosis is often present. Musculoskeletal complications may be amenable to supportive intervention. Structured rehabilitation programs were associated with functional improvement in ankle contractures in children with Cockayne syndrome, underscoring the importance of early and ongoing physical therapy as part of multidisciplinary care (22).

Dentition anomalies. Deficient hygiene, gingivitis, cervical caries, enamel hypoplasia, abnormal position of the upper and inferior lateral incisors, and macrodontia of the upper central teeth have been described (09).

Other features. Other features include functional renal abnormalities and signs of endocrine dysfunction, including undescended testes, micropenis, and irregular menses (85). A retrospective study of 136 genetically confirmed patients with Cockayne syndrome showed that 69% had a renal disorder or elevated blood pressure, 62% had proteinuria, 45% had a decreased glomerular filtration rate, and 72% had hyperuricemia (113). There was no correlation with the genetic background or clinical types of Cockayne syndrome. Funaki and colleagues described Cockayne syndrome with recurrent acute tubulointerstitial nephritis, suggesting that rapid deterioration of the renal function in Cockayne syndrome patients might be the result of acute tubulointerstitial nephritis (36). The nephrotic syndrome in their patient seemed to be accompanied by acute tubulointerstitial nephritis, as in other reports. Variability in the renal findings of siblings indicates that no obvious genotype-phenotype correlation exists; some renal changes may be related to premature aging (12).

A case of dilated cardiomyopathy has been reported, but cardiac involvement in general, has not been described in Cockayne syndrome patients. Ovaert and colleagues report on one patient in whom marked ascending aorta dilatation was observed together with mild aortic regurgitation (89). Some atypical presentations, such as familial hemiplegic migraine, have been described in three full siblings with CSB who repeatedly presented with transient focal neurologic deficits and headache (21).

In patients with Cockayne syndrome, elevated lymphocyte counts, increased intermediate and non-classical monocytes, and high IL-8 levels indicate a pro-inflammatory state. The presence of senescent CD8+ CD28- CD27- T cells suggests immunosenescence, resembling that in elderly individuals, potentially explaining their heightened infection susceptibility due to aging-related inflammation (132).

Bulbar involvement contributes substantially to morbidity in Cockayne syndrome. Systematic evaluation has demonstrated high rates of dysphagia, impaired oral motor control, and communication difficulties, with important implications for aspiration risk, nutrition, and quality of life (111). Early assessment and ongoing involvement of speech-language pathology are recommended.

Hepatic dysfunction may represent an underrecognized component of Cockayne syndrome, particularly in ERCC8-related disease. In a clinical series, elevated liver enzymes were frequently observed and proposed as a potential biomarker, even in the absence of overt liver disease (22). Anhidrosis was also identified as a rare autonomic manifestation, further expanding the recognized clinical spectrum.

Prognosis and complications

The disease is progressive, although it often remains at a plateau for years. Many of the individuals die in late childhood or early adulthood of inanition, infection, or atherosclerosis. Rarely, and for unexplained reasons, the course for some patients with Cockayne syndrome is slower than usual, resulting in survival into adulthood. Rapin and colleagues report the clinical course and pathology of a man with Cockayne syndrome group A who died at the age of 31-and-a-half years with 15 adequately documented other adults with Cockayne syndrome and five with xeroderma pigmentosum-Cockayne syndrome complex (98).

Death generally occurs by the age of 30, secondary to inanition or infection.

Biological basis

Etiology and pathogenesis

Cockayne syndrome as a disorder of transcriptional stress responses. Cockayne syndrome is an autosomal recessive progeroid disorder caused by pathogenic variants in genes encoding proteins essential for transcription-coupled nucleotide excision repair (TC-NER), most commonly ERCC6 (CSB) and less frequently ERCC8 (CSA). Historically, Cockayne syndrome has been conceptualized as a DNA repair disorder characterized by defective recovery of RNA synthesis after ultraviolet (UV) irradiation (72). However, accumulating evidence indicates that Cockayne syndrome represents a broader disorder of transcriptional homeostasis in which failure to appropriately respond to transcription-blocking DNA damage, oxidative stress, and chromatin perturbations lead to impaired development, accelerated aging, and progressive neurodegeneration (18; 56). Activation of the integrated stress response has been demonstrated in Cockayne syndrome–associated XPG mutations, further supporting a disease model centered on chronic transcriptional stress and maladaptive cellular stress signaling rather than isolated DNA repair failure (133).

Transcription-coupled nucleotide excision repair (TC-NER): classical framework. TC-NER selectively removes bulky DNA lesions from the transcribed strand of active genes. On encountering a DNA lesion, RNA polymerase II stalls, triggering recruitment of CSB and CSA, which coordinate chromatin remodeling, transcriptional arrest, and assembly of downstream repair factors, including TFIIH (43; 33; 54). In Cockayne syndrome cells, RNA synthesis fails to recover following UV irradiation because transcription-blocking lesions are not efficiently removed from active genes (72). Although xeroderma pigmentosum cells also exhibit impaired nucleotide excision repair, they typically retain TC-NER activity and do not develop the characteristic neurodegeneration of Cockayne syndrome, highlighting that defective TC-NER alone is insufficient to explain the full phenotype (33; 18).

CSB as a regulator of transcription-associated chromatin dynamics. Beyond its role in TC-NER, CSB functions as a DNA-dependent ATPase involved in chromatin remodeling and transcription regulation (122; 82). CSB interacts dynamically with RNA polymerase II, modulates nucleosome positioning, and influences transcription elongation under both basal and stress conditions.

Recent work has clarified that CSB acts as a central coordinator of transcription-associated chromatin dynamics, regulating chromatin accessibility and RNA polymerase II progression during both homeostatic transcription and genotoxic stress. CSB deficiency leads to widespread transcriptional dysregulation and altered chromatin architecture, reinforcing the concept that Cockayne syndrome is fundamentally a disorder of transcriptional stress adaptation rather than a narrowly defined DNA repair defect (14; 75).

Expansion of transcription-coupled repair beyond UV-induced lesions. Although TC-NER was initially described in response to UV-induced DNA damage, transcription-coupled repair pathways are now recognized to process a broader spectrum of transcription-blocking lesions. These include oxidative base damage, abasic sites, and DNA–protein crosslinks (56).

Studies demonstrate that transcription-coupled mechanisms play a key role in the resolution of DNA–protein crosslinks within actively transcribed regions. These bulky lesions stall RNA polymerase II and require coordinated proteolysis, chromatin remodeling, and repair factor recruitment, processes in which CSB-dependent chromatin remodeling appears to be critical (05; 20; 102). Defective clearance of transcription-blocking DNA–protein crosslinks likely represents an additional source of persistent genomic stress in Cockayne syndrome.

Oxidative stress, mitochondrial dysfunction, and cellular aging. Cells from patients with Cockayne syndrome exhibit hypersensitivity to oxidative stress and increased accumulation of oxidative DNA lesions (07; 74). CSB participates in base excision repair and contributes to mitochondrial homeostasis, linking nuclear DNA repair defects to mitochondrial dysfunction and altered redox balance (56; 88). ERCC6 deficiency is associated with increased oxidative metabolism and heightened sensitivity to environmental and pharmacologic stressors. In an ercc6-deficient zebrafish model, ultraviolet and metronidazole exposure caused exaggerated toxicity accompanied by increased oxygen consumption and impaired sensory function (48).

Evidence further supports a direct role for CSB in protecting genome integrity under oxidative stress. CSB-deficient human cells display increased genomic instability and impaired recovery following oxidative damage, strengthening the link between oxidative stress, transcriptional failure, and accelerated aging in Cockayne syndrome (77).

Experimental models of Cockayne syndrome demonstrate systemic metabolic involvement beyond the nervous system. In murine models, Cockayne syndrome was associated with progressive kidney disease and impaired de novo NAD⁺ biosynthesis, linking defective DNA repair to mitochondrial dysfunction and metabolic stress (93).

Cellular senescence and accelerated aging. Premature aging features in Cockayne syndrome have been attributed to chronic transcriptional stress, oxidative damage, and impaired proteostasis (43; 105). Genome-wide DNA methylation analyses demonstrate that Cockayne syndrome shares epigenetic signatures with physiological aging, supporting the concept of accelerated aging rather than aberrant development alone (30).

Experimental data now indicate that CSB dosage modulates cellular susceptibility to stress-induced senescence. Subpopulations of human dermal fibroblasts overexpressing CSB resist UVB-induced premature senescence, suggesting that CSB acts as a buffering factor against senescence-inducing transcriptional stress and further reinforcing the accelerated aging model of Cockayne syndrome (35).

Dysregulated signaling pathways, inflammation, and neurodegeneration. Neurodegeneration in Cockayne syndrome reflects both neurodevelopmental impairment and progressive neuronal loss (24; 128). Transcriptomic and proteomic studies have identified alterations in pathways related to synaptic function, neuronal differentiation, and growth hormone/IGF-1 signaling (128).

Pathway analyses reveal broader dysregulation of MAPK and PI3K–Akt signaling, extracellular matrix remodeling, inflammatory pathways, and neuronal signaling networks in Cockayne syndrome models. These findings suggest that CSB deficiency disrupts multiple stress-response and survival pathways, contributing to neurodegeneration, vascular abnormalities, and systemic features of the disease (55). Comprehensive reviews of transcription-coupled nucleotide excision repair emphasize its dual role in lesion removal and transcriptional surveillance, providing a unifying framework for understanding neurodegeneration and systemic decline in Cockayne syndrome (125).

Integrated model of Cockayne syndrome pathogenesis. Taken together, Cockayne syndrome is best understood as a multisystem disorder arising from failure of transcription-associated stress responses. Defective CSB and CSA function impairs chromatin remodeling, transcriptional recovery, and lesion resolution within actively transcribed genes, leading to cumulative transcriptional arrest, oxidative damage, mitochondrial dysfunction, cellular senescence, and neurodegeneration.

An integrative synthesis emphasizes that CSB dysfunction simultaneously affects transcription regulation, chromatin architecture, ribosomal biogenesis, mitochondrial function, and stress signaling, providing a unifying framework that links impaired neurodevelopment with progressive neurodegeneration and accelerated aging in Cockayne syndrome (02).

Differential diagnosis

Hereditary diseases characterized by genetic defects of DNA repair include ataxia telangiectasia, Nijmegen breakage syndrome, Werner syndrome, Bloom Syndrome, Fanconi anemia, xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. They share many clinical features such as growth retardation; neurologic disorders; premature aging; skin alterations including abnormal pigmentation; telangiectasia; xerosis cutis; pathological wound healing; as well as an increased risk of developing different types of cancer (61).

Cockayne syndrome is distinctive, especially in older individuals, but may overlap with xeroderma pigmentosum. Xeroderma pigmentosum is generally distinguished from Cockayne syndrome by the increased incidence of skin neoplasms in xeroderma pigmentosum. There have now been at least three forms of xeroderma pigmentosum determined by complementation where the individual has had some features of Cockayne syndrome. There have also been reports of two patients with the features of DeSanctis-Cacchione syndrome, a subtype of xeroderma pigmentosum with complementation studies consistent with a defect in Cockayne syndrome type B, or ERCC6, indicating some degree of phenotype heterogeneity (53). The difference in incidence of cancer may be due to the fact that UV exposure in Cockayne syndrome results in cell lethality but not mutagenesis (100). Owing to phenotypic overlap with other DNA repair disorders, such as subsets of xeroderma pigmentosa and trichothiodystrophy, individuals who present with clinical signs of Cockayne syndrome may also have pathogenic variants in ERCC1, ERCC2 (XPD), ERCC3 (XPB), ERCC4 (XPF), ERCC5 (XPG), and XPA.

As a leukodystrophy, the tigroid pattern of involvement needs to be distinguished from the connatal form of Pelizaeus-Merzbacher. However, the other clinical features should allow discernment.

When cardinal features are lacking, the diagnosis of Cockayne syndrome should be considered if presented with growth retardation, microcephaly, and one of the suggesting features, such as enophthalmia, limb ataxia, abnormal auditory evoked responses, or increased ventricular size on cerebral imaging (92).

A study has indicated that some forms of MORC2-related disorder have phenotypic similarities to Cockayne syndrome, including features of accelerated aging (112). Microrchidia CW-type zinc finger 2 (MORC2; MIM 616688), is part of a superfamily of proteins involved in chromatin remodeling, epigenetic transcriptional regulation, DNA repair, and fatty acid biosynthesis. Hence, MORC2 should be included in diagnostic genetic test panels targeting the evaluation of microcephaly or suspected DNA repair disorders. Further studies are needed to elucidate the specific molecular mechanisms by which these phenotypes arise.

UV-sensitive syndrome is another rare autosomal recessive and transcription-coupled NER disorder with different clinical manifestations, although some types are allelic. The Cockayne syndrome–like phenotype has been associated with a defective UVSSA gene (11).

DYRK1A haploinsufficiency syndrome is being recognized as a differential diagnosis for NER disorders. DYRK1A symptoms overlap with Cockayne syndrome, with shared features, such as intellectual disability and microcephaly, systematically present in both disorders. Other common symptoms include feeding difficulties, abnormal brain imaging, ataxic gait, hypertonia, and deep-set eyes. However, distinctive features of DYRK1A syndrome, such as severely impaired language, febrile seizures, and autistic behavior or anxiety, help differentiate it from Cockayne syndrome, which typically manifests with severe growth delay, bilateral cataracts, and pigmentary retinopathy. DYRK1A patient-derived cell lines did not exhibit NER defects and did not share the Cockayne syndrome transcriptomic signature, suggesting that if clinical symptoms overlap stems from common molecular disruptions, DYRK1A is involved downstream of the Cockayne syndrome genes (73).

Diagnostic workup

The diagnosis is established by the identification of biallelic pathogenic variants in the ERCC6 or ERCC8 genes. Mutations in the ERCC6 gene make up approximately 70% of cases. The majority of pathogenic variants are picked by sequence analysis, and 10% to 12% may need gene-targeted deletion/duplication analysis (68; 19). Most variants are predicted loss-of-function variants.

DNA repair assay. The hallmark of Cockayne syndrome is the failure of RNA synthesis to recover after ultraviolet irradiation. After irradiation, RNA synthesis is depressed in both normal and Cockayne syndrome cells but recovers rapidly in normal cells. It fails to do so in cells with the biochemical defect of Cockayne syndrome. This rapid recovery in normal cells is due to the preferential repair of DNA in transcribed regions, which does not occur in Cockayne syndrome (71). If the diagnosis of Cockayne syndrome is strongly suspected, but the molecular genetic testing does not identify pathogenic variants in one of the associated genes, an assay of the cellular phenotype can be considered. DNA repair assay is performed on skin fibroblasts (83).

Very early prenatal diagnosis of Cockayne syndrome has been done by coelocentesis at 8 weeks of gestation by aspiration of coelomic fluid from the coelomic cavity (38).

Additional studies that aid in the diagnosis include ophthalmological examination for cataracts and retinopathy (119); nerve conduction velocity or nerve biopsy examining for peripheral neuropathy (108; 39; 129); electromyography for the identification of demyelinating peripheral myopathy (15); CT scan for cerebral calcifications (31); MRI showing abnormalities of myelination (16); and skeletal radiographs showing thickened skull, intracranial calcifications, marble epiphyses in the terminal phalanges of the hands, protrusion of the anterior aspect of the vertebral bodies, and hypoplasia of the iliac wings (25).

Adachi and colleagues describe MRI findings of small patchy subcortical lesions visualized as areas of high intensity on diffusion-weighted images and low intensity on FLAIR images, suggestive of active demyelinating lesions (01). Koob and colleagues describe the neuroimaging characteristics of Cockayne syndrome (63). Hypomyelination was more severe in early onset disease than the late onset, though the latter also showed less cerebral atrophy. Atrophy involves the supratentorial white matter, cerebellum, corpus callosum, and brain stem. Calcifications seen were characteristically in the sulcal depths of the cortex. Putamen and dentate nuclei calcifications can occur as well. SPECT scans revealed presence of lactate and decreased choline and NAA ratios. Diffusion tensor imaging with volumetric analysis has been used to quantify atrophy and white matter abnormalities (64).

Kleijer and colleagues evaluated the results of 29 prenatal diagnoses for Cockayne syndrome in a consecutive series. They conclude that reliable prenatal diagnosis of the Cockayne syndrome can be made by the demonstration of a strongly reduced recovery of DNA-synthesis in ultraviolet-irradiated cultured chorionic villus cells or amniocytes (60). Assessment of the recovery of RNA-synthesis was needed as an adjunctive method in rare cases of poor cell growth and DNA-synthesis. Performing immunohistochemistry in autopsy brains and ELISA in the cerebrospinal fluid and urine of patients with hereditary DNA repair disorders, Hayashi and colleagues report that increased oxidative DNA damage and lipid peroxidation were noted in the presence of degeneration of basal ganglia, intracerebral calcification, and cerebellar degeneration in patients with xeroderma pigmentosum, Cockayne syndrome, and ataxia-telangiectasia-like disorder, respectively (46). Increased serum neurofilament light-chain (sNFL) has been proposed as a peripheral biomarker to reflect disease severity in Cockayne syndrome (104). However, larger studies are needed to validate its role as a diagnostic or prognostic marker.

Pathogenic synonymous variants affecting splicing may underlie classical Cockayne syndrome phenotypes. Such cases emphasize the need for transcript-level analysis in molecular diagnosis, particularly when clinical suspicion is high despite atypical sequence findings (13).

Genetic counseling. Genetic counseling is an integral part of patient care in those with this syndrome or those suspected of having it. Cockayne syndrome is inherited in an autosomal recessive manner. Reproduction has not been reported in any individual with Cockayne syndrome. Atypical cases may require molecular genetic testing. The two genes responsible for Cockayne syndrome are ERCC6 for 65% to 75% of individuals (120) and ERCC8 for 25% to 35% of individuals (47; 90). Sequence analysis for both genes is clinically available. Prenatal testing is available through laboratories offering custom prenatal testing. Carrier detection (50% chance of being an asymptomatic carrier) is available once the mutations have been identified in the proband.

Family support groups are an important adjunct and can be collaborative, assuming appropriate boundaries—ethical, professional, geographic, and other—are recognized (131).

National rare disease research networks. National rare disease research networks integrating patient registries, standardized diagnostic pathways, and multidisciplinary expertise have been established for gene mutation-related intractable skin diseases, including nucleotide excision repair disorders. Such coordinated infrastructures facilitate early diagnosis, longitudinal follow-up, and access to specialized centers (45).

Management

General principles. Management of Cockayne syndrome remains supportive and multidisciplinary. There is no established disease-modifying therapy. Care is directed toward optimizing nutrition, neurologic function, mobility, sensory support, and monitoring for systemic complications.

Advances in the understanding of nucleotide excision repair disorders have reframed Cockayne syndrome as a disorder of transcription-associated stress, oxidative damage, and mitochondrial dysfunction. This evolving framework has prompted interest in mechanism-informed therapeutic strategies, although clinical translation remains investigational (116).

Multidisciplinary and longitudinal care. Patients benefit from coordinated care involving neurology, genetics, gastroenterology, ophthalmology, audiology, orthopedics, rehabilitation medicine, and nutrition. Long-term follow-up is essential because of progressive neurologic and multisystem involvement.

Nutritional and metabolic management. Failure to thrive and cachexia are common and may necessitate high-calorie nutritional support and enteral feeding tubes or even gastrostomy to avoid malnutrition because of poor oral intake, muscle weakness, or neurologic impairment.

Preclinical studies in DNA repair–deficient models suggest that modulation of oxidative stress responses and metabolic pathways may influence disease progression. Although such approaches are not yet standard of care, they inform emerging therapeutic concepts in Cockayne syndrome (116).

Photosensitivity. Individuals with photosensitivity should avoid UV light from the sun or some artificial lights, including neon and halogen. Preventive measures include hats with a large brim, clothes that block UV, closed collars, and use of sunscreen with greater than 50 SPF during activities and trips outside, even in the winter or late afternoon when the brightness seems low. The eyes must also be protected by special glasses or a mask filtering the UV.

Ocular abnormalities. A significant proportion will require cataract extraction at an early age, which may present technical difficulties due to enophthalmos, which is a constant finding, with poor pupillary dilation and growth retardation. The fitting and assessment of aphakic contact lenses during the postoperative period also requires great skill. Strabismus, when it exists, must be taken care of very early.

Dental care. Horbelt reports that the dental care, procedures, and intervention offered to patients with Cockayne syndrome do not differ much from that given to any other patient (50).

Other measures. Patients should be monitored for treatable complications, including progressive hearing and visual loss, hypertension, and renal problems. Cochlear implants are successful in managing progressive hearing loss (126) and improving language outcomes (65).

In their study, Motojima and colleagues evaluated the longitudinal changes in serum creatinine and serum cystatin C levels in three patients with Cockayne syndrome and found that the serum creatinine level in these patients gradually exceeded the reference level from five to seven years of age, after correcting for body length (81). The cystatin C level of the Cockayne syndrome patients increased to above the reference level whereas their estimated glomerular filtration rate remained within stage 2 or 3, showing that serum creatinine level is useful for the evaluation of renal function in Cockayne syndrome, which further helps in clinical management of patients.

Use of appropriate psychomotor rehabilitation, physiotherapy, and assistive devices to support the body in a good position (eg, corset) and allow movement (eg, canes, walker, wheelchair), even with neurologic decline, optimize the patient's well-being. Neilan and colleagues studied the effect of carbidopa-levodopa therapy in three patients with Cockayne syndrome (86). Main outcome measures included status of tremors, ability to perform daily tasks, serial physical examinations, and results of handwriting samples. They found that all three patients had a clear reduction in tremors and improvements in handwriting and manipulation of utensils and cups. GPi-pallidal stimulation has been used to treat generalized dystonia in Cockayne syndrome (42). Botulinum toxin injection has been used in a child with lower limb spasticity with encouraging results (51). Deep brain stimulation for Cockayne syndrome–associated movement disorder has also been tried for symptomatic relief (32).

Use of weight-appropriate rather than age-appropriate airway equipment must be a consideration in the perioperative management of Cockayne syndrome. Because of premature aging, the “adult” plateau in development is often attained in early childhood in severe cases. Hence, in these patients, recognition of advanced physiological age vis-à-vis their somatic appearance is essential for successful management (96).

Environmental and genotoxic exposure considerations. Emerging data indicate that certain bulky DNA adducts, including those induced by environmental toxins such as aflatoxin B1, are substrates for transcription-coupled nucleotide excision repair (70). Although direct clinical evidence in Cockayne syndrome is lacking, minimizing exposure to environmental genotoxins is biologically prudent given underlying DNA repair deficiency. Similarly, evolving understanding of transcription-coupled repair dynamics underscores the vulnerability of actively transcribed genes to genotoxic stress in nucleotide excision repair disorders (57). These observations support general counseling to avoid unnecessary genotoxic exposures, including tobacco smoke and known environmental carcinogens.

Emerging and future therapies. As more information regarding genetic mechanisms is obtained, molecular therapy may become available. A number of signaling pathways are involved in nucleotide excision repair and could be used in future therapies (62). Studies have shown evidence for mitochondrial dysfunction in Cockayne syndrome, which likely contributes to the severe premature aging phenotype of this disease (88). NAD+ has been shown to be reduced in Cockayne syndrome, and short-term treatment (10 days) with the NAD+ precursor nicotinamide riboside has been shown to prevent hearing loss, restore outer hair cell loss, and improve cochlear health in mouse models of Cockayne syndrome (88). One model for gene rescue has proven successful in Cockayne stem cells (130). Information gained from this approach could have ramifications, not only for Cockayne syndrome, but for general aging as well (56). Because CSB is often overexpressed in cancer cells, its clinically induced downregulation may prove to be therapeutic (95). Necdin, a member of the melanoma-associated antigen protein family, has been identified as a target for the CSB protein (76). Loss of functional CSB leads to aberrant hyperactivation of Necdin that adversely affects neurogenesis and survival of postmitotic neurons. Thus, Necdin could serve as a prominent molecular marker for therapeutic intervention. Senomorphic drugs, such as trametinib, reduced senescent cell load and affected other aspects of the senescence phenotype (including splicing factor expression) in Cockayne syndrome cell cultures (17) and could be a useful adjunct to therapy for progeroid diseases.

Several experimental therapies are underway. Supplementation with nicotinamide has been shown to limit accelerated aging in affected individuals with Cockayne syndrome and restore antioxidant defenses (23).

Advances in molecular genetics and DNA repair biology have expanded the therapeutic horizon for nucleotide excision repair disorders. Experimental strategies aimed at enhancing cellular stress resilience, modulating oxidative damage, and correcting underlying genetic defects are under active investigation. Although gene-targeted and genome-editing approaches remain investigational, they represent potential future disease-modifying options for Cockayne syndrome (116). In an ercc6-deficient zebrafish model, functional deficits were partially rescued by treatment with a superoxide dismutase mimetic, providing experimental support for antioxidant-based therapeutic strategies; however, clinical applicability remains unproven (48).

Agents and circumstances to avoid

Ultraviolet radiation. Patients with Cockayne syndrome exhibit marked photosensitivity due to defective transcription-coupled nucleotide excision repair. Ultraviolet (UV) exposure may provoke exaggerated sunburn reactions. Although skin cancer risk is not increased as in xeroderma pigmentosum, strict photoprotection, including sun avoidance, protective clothing, and high-SPF sunscreen, is recommended.

Hepatotoxic medications. Underlying mitochondrial vulnerability and impaired cellular stress responses may increase susceptibility to drug-induced liver injury. Clinicians should also exercise caution with other medications known to impair mitochondrial function or provoke hepatotoxicity.

Metronidazole should be used with caution in patients with Cockayne syndrome. Severe hepatotoxicity, including acute liver failure, has been reported in affected children following metronidazole exposure (03). Given underlying mitochondrial dysfunction and altered stress-response pathways, patients with Cockayne syndrome may be at increased risk for drug-induced liver injury. Alternative antimicrobial agents should be considered whenever feasible, and close monitoring of liver function is advised if metronidazole exposure is unavoidable.

General metabolic and physiologic stress. Because Cockayne syndrome represents a disorder of impaired transcriptional and oxidative stress responses, prolonged fasting, dehydration, severe infection, and other systemic stressors may precipitate clinical deterioration. Early supportive care during intercurrent illness is recommended.

Special considerations

Pregnancy

Two successful deliveries by mothers with Cockayne syndrome have been reported (99; 101). Spinal anesthesia is preferred, because of the variety of anomalies (eg, cardiorespiratory and neuromuscular) that may be present. Pregnancy with an affected fetus is normal. Conte and colleagues describe a molecular prenatal diagnosis of Cockayne syndrome type A for the first time (28).

Anesthesia

Children and adults with Cockayne syndrome often require surgical or dental procedures because of growth abnormalities, orthopedic complications, or dental disease. Multisystem involvement, including neurologic impairment, cachexia, airway abnormalities, and possible autonomic dysfunction, may complicate perioperative management. Intubation can be difficult because of the small mandible, oral cavity, and larynx, compounded by the patient's mental retardation, blindness, and deafness (29). Potential airway management challenges in the context of contemporary anesthetic techniques should be anticipated in these patients, and video laryngoscopy may be beneficial (04). Electroencephalography has been used to ascertain anesthetic depth in the CNS and to titrate levels of anesthesia during dental surgery (123).

Patients with DNA repair disorders, including Cockayne syndrome, may exhibit increased perioperative vulnerability related to impaired DNA damage responses, altered pharmacodynamics, and multisystem disease. Careful anesthetic planning, avoidance of prolonged hypotension, and vigilant perioperative monitoring are recommended (06).

Autonomic instability may further complicate anesthetic management. An unusual hypertensive response to local anesthetic administration has been reported in a patient with Cockayne syndrome undergoing dental surgery under general anesthesia (107), underscoring the importance of continuous cardiovascular monitoring and individualized anesthetic strategies.

Malignancy

The first reported malignancy associated with Cockayne syndrome was described in a 3.5-year-old girl with CSB and undifferentiated embryonal sarcoma of the liver (117). CSA and CSB are integral to transcription-coupled nucleotide excision repair (TC-NER) and linked to other DNA repair pathways, partly via direct protein interactions. However, in contrast to other DNA repair defective syndromes, it was noted not to predispose to cancer (100). The association of Cockayne syndrome with undifferentiated embryonal sarcoma of the liver shows that individuals with Cockayne syndrome can develop malignancies.

References

01: Adachi M, Kawanami T, Ohshima F, Hosoya T. MRI findings of cerebral white matter in Cockayne syndrome. Magn Reson Med Sci 2006;5(1):41-5. PMID 16785726
02: Afonso-Reis R, Madeira CR, Brito DVC, Nóbrega C. Insights into Cockayne syndrome type B: what underlies its pathogenesis? Aging Cell 2025;24(7):e70136. PMID 40536083
03: Agrawal A, Ghosh U, Srinivasan VM. Metronidazole-induced hepatotoxicity in children with Cockayne syndrome. Indian J Pediatr 2026;93(2):204. PMID 41354724
04: Aldridge D, Wisely N. Airway management in a patient with Cockayne syndrome. Anaesth Rep 2024;12(1):e12292. PMID 38645477
05: Alshareef D, Nguyen CT, Tucker KN, Gearhart MD, Tretyakova NY, Campbell C. Genome-wide mapping of formaldehyde-induced DNA-protein crosslinks reveals unique patterns of formation and transcription-coupled removal in mammalian cells. Nucleic Acids Res 2025;53(14):gkaf720. PMID 40744501
06: Anandanadesan R, Tupprasoot R. Anaesthesia for children with DNA repair disorders. BJA Educ 2025;25(9):343-7. PMID 40842920
07: Andrade LN, Nathanson JL, Yeo GW, Menck CF, Muotri AR. Evidence for premature aging due to oxidative stress in iPSCs from Cockayne syndrome. Hum Mol Genet 2012;21(17):3825-34. PMID 22661500
08: Andrews AD, Barrett SF, Yoder FW, Robbins JH. Cockayne’s Syndrome fibroblasts have increased sensitivity to ultraviolet light but normal rates of unscheduled DNA synthesis. J Invest Dermatol 1978;70(5):237-9. PMID 641373
09: Arenas-Sordo L, Hernandez-Zamora E, Montoya-Perez LA, Aldape-Barrios BC. Cockayne’s syndrome: a case report. Literature review. Med Oral Patol Oral Cir Bucal 2006;11(3):E236-8. PMID 16648759
10: Baer S, Tuzin N, Kang PB, et al. Growth charts in Cockayne syndrome type 1 and type 2. Eur J Med Genet 2021;64(1):104105. PMID 33227433
11: Bahap Y, Kayhan G. A Cockayne-syndrome-like phenotype with a homozygous truncating UVSSA variant: might this be a new cause? Mol Syndromol 2024;15(4):324-7. PMID 39119453
12: Ben Chehida A, Ghali N, Ben Abdelaziz R, Ben Moussa F, Tebib N. Renal involvement in 2 siblings with Cockayne syndrome. Iran J Kidney Dis 2017;11(3):253-5. PMID 28575888
13: Bie X, Liu L, Liu L, et al. Clinical and molecular genetic analysis of a Chinese patient with Cockayne syndrome caused by ERCC8 gene synonymous variant at splicing site and exon 1 deletion. Orphanet J Rare Dis 2025;20(1):610. PMID 41299792
14: Bilkis R, Lake RJ, Fan HY. ATP-dependent chromatin remodeler CSB couples DNA repair pathways to transcription with implications for Cockayne syndrome and cancer therapy. Cells 2025;14(4):239. PMID 39996712
15: Blin-Rochemaure N, Allani-Essid N, Carlier R, et al. The place of neuropathy in the early diagnosis of Cockayne syndrome: report on two siblings [Article in French]. Arch Pediatr 2017;24(4):353-9. PMID 28258862
16: Boltshauser E, Yalcinkaya C, Wichmann W, Reutter F, Prader A, Valavanis A. MRI in Cockayne syndrome type I. Neuroradiology 1989;31:276-7. PMID 2779780
17: Bramwell LR, Harries LW. Senescence, regulators of alternative splicing and effects of trametinib treatment in progeroid syndromes. Geroscience 2024;46(2):1861-79. PMID 37751047
18: Brooks PJ. Blinded by the UV light: How the focus on transcription-coupled NER has distracted from understanding the mechanisms of Cockayne syndrome neurologic disease. DNA Repair (Amst) 2013;12(8):656-71. PMID 23683874
19: Calmels N, Botta E, Jia N, et al. Functional and clinical relevance of novel mutations in a large cohort of patients with Cockayne syndrome. J Med Genet 2018;55(5):329-43. PMID 29572252
20: Carnie CJ, Jackson SP, Stingele J. Transcription-coupled repair of DNA-protein crosslinks. Trends Cell Biol 2025;35(4):316-29. PMID 39617652
21: Carroll J, Pabst L, Koboldt DC, et al. Novel presentation of hemiplegic migraine in a patient with Cockayne syndrome. Pediatr Neurol 2023;138:95-7. PMID 36434915
22: Chen J, Su W, Gao D, et al. Clinical and genetic analysis of ERCC8-related Cockayne syndrome: hepatic dysfunction as a biomarker, anhidrosis as a rare feature, and rehabilitation outcomes for ankle contractures. Front Genet 2025;16:1591551. PMID 40842628
23: Chikhaoui A, Zayoud K, Kraoua I, et al. Supplementation with nicotinamide limits accelerated aging in affected individuals with Cockayne syndrome and restores antioxidant defenses. Aging (Albany NY) 2024;16(21):13271-87. PMID 39611850
24: Ciaffardini F, Nicolai S, Caputo M, Canu G, et al. The cockayne syndrome B protein is essential for neuronal differentiation and neuritogenesis. Cell Death Dis 2014;5:e1268. PMID 24874740
25: Cirillo Silengo M, Franceschini P, Bianco R, et al. Distinctive skeletal dysplasia in Cockayne syndrome. Pediatr Radiol 1986;16:264-6. PMID 3703607
26: Cockayne EA. Dwarfism with retinal atrophy and deafness. Arch Dis Child 1936;11:1-8. PMID 21032019
27: Cockayne EA. Dwarfism with retinal atrophy and deafness. Arch Dis Child 1946;21:52-4. PMID 20989207
28: Conte C, D'Apice MR, Botta A, Sangiuolo F, Novelli G. Prenatal diagnosis of Cockayne syndrome type A based on the identification of two novel mutations in the ERCC8 gene. Genet Test Mol Biomarkers 2009;13(1):127-31. PMID 19309286
29: Cook S. Cockayne's syndrome. Another cause of difficult intubation. Anaesthesia 1982;37:1104-7. PMID 7137557
30: Crochemore C, Chica C, Garagnani P, et al. Epigenomic signature of accelerated ageing in progeroid Cockayne syndrome. Aging Cell 2023;22(10):e13959. PMID 37688320
31: Demaerel P, Kendall BE, Kingsley D. Cranial CT and MRI in diseases with DNA repair defects. Neuroradiology 1992;34:117-21. PMID 1603308
32: Domino JS, Gelineau-Morel R, Kaufman C. Deep brain stimulation for Cockayne syndrome-associated movement disorder. J Mov Disord 2022;15(1):62-5. PMID 34724781
33: Drapkin R, Sancar A, Reinberg D. Where transcription meets repair. Cell 1994;77:9-12. PMID 8156601
34: Figueras-Roca M, Budi V, Morató M, Camós-Carreras A, Muñoz JE, Sánchez-Dalmau B. Cockayne syndrome in adults: complete retinal dysfunction exploration of two case reports. Doc Ophthalmol 2019;138(3):241-6. PMID 30820731
35: Fotopoulou A, Angelopoulou MT, Pratsinis H, Mavrogonatou E, Kletsas D. A subset of human dermal fibroblasts overexpressing Cockayne syndrome group B protein resist UVB radiation-mediated premature senescence. Aging Cell 2025;24(3):e14422. PMID 39698891
36: Funaki S, Takahashi S, Murakami H, Harada K, Kitamura H. Cockayne syndrome with recurrent acute tubulointerstitial nephritis. Pathol Int 2006;56(11):678-82. PMID 17040291
37: Ghosh R, León-Ruiz M, Mondal AS, Dubey S, Benito-León J. Cockayne syndrome B with axonal sensorimotor polyneuropathy caused by a de novo mutation of the gene ERCC6: a novel phenotypic and genotypic variant. Neurologia (Engl Ed) 2025;40(5):484-7. PMID 40523717
38: Giambona A, Vinciguerra M, Leto F, et al. Very early prenatal diagnosis of Cockayne's syndrome by coelocentesis. J Obstet Gynaecol 2022;42(5):1524-31. PMID 35006018
39: Grunnet ML, Zimmerman AW, Lewis RA. Ultrastructure and electrodiagnosis of peripheral neuropathy in Cockayne's syndrome. Neurology 1983;33:1606-9. PMID 6316205
40: Gultekin-Zaim OB, Yalçın-Çakmaklı G, Çolpak Aİ, et al. Cockayne syndrome type 3 with dystonia-ataxia and clicking blinks. Mov Disord Clin Pract 2023;10(Suppl 3):S48-50. PMID 37636235
41: Hafsi W, Badri T. Cockayne syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing; August 16, 2020. PMID 30252254
42: Hamasaki K, Yamada K, Hamasaki T, Kuratsu J. GPi-pallidal stimulation to treat generalized dystonia in Cockayne syndrome. Mov Disord 2010;25(5):656-8. PMID 20131400
43: Hanawalt PC. Transcription-coupled repair and human disease. Science 1994;266:1957-8. PMID 7801121
44: Handzel O, Nadol JB Jr. Temporal bone histopathology in Cockayne syndrome. Otol Neurotol 2018;39(5):e387-91. PMID 29649050
45: Hashimoto T, Moriwaki SI, Iwata H, et al. Activities of the Research Group for Comprehensive Research of Gene Mutation-related Rare and Intractable Diseases of the Skin within the Project for Research on Intractable Diseases of the Ministry of Health, Labor, and Welfare of Japan. Keio J Med 2025;74(1):4-10. PMID 39710404
46: Hayashi M, Miyata R, Tanuma N. Oxidative stress in developmental brain disorders. Adv Exp Med Biol 2012;724:278-90. PMID 22411250
47: Henning KA, Li L, Iyer N, et al. The Cockayne syndrome group A encodes a WD repeat protein that interacts with CSB protein and a subunit of RNA polymerase II TFIIH. Cell 1995;82:555-64. PMID 7664335
48: Hernandez Herrera GA, Dugdale JA, Wallace JG, et al. ercc6-deficient zebrafish exhibit UV and metronidazole sensitivity, increased oxygen consumption, and impaired hair cell mechanoelectrical transduction which can be restored by the superoxide dismutase mimetic MnTBAP. Hum Mol Genet 2026;35(4):ddaf203. PMID 41527836
49: Hoag A, Duan M, Mao P. The role of transcription cactor IIH complex in nucleotide excision repair. Environ Mol Mutagen 2024;65 (Suppl 1):72-81. PMID 37545038
50: Horbelt CV. Robinow syndrome, Cockayne syndrome, and Pfeiffer syndrome: an overview of physical, neurological, and oral characteristics. Gen Dent 2010;58(1):14-7. PMID 20129888
51: Hsu LC, Chiang PY, Lin WP, et al. Botulinum toxin injection for Cockayne syndrome with muscle spasticity over bilateral lower limbs: a case report. World J Clin Cases 2021;9(18):4728-33. PMID 34222439
52: Huang Y, Gu L, Li GM. Heat shock protein DNAJA2 regulates transcription-coupled repair by triggering CSB degradation via chaperone-mediated autophagy. Cell Discov 2023;9(1):107. PMID 37907457
53: Itoh T, Cleaver JE, Yamaizumi M. Cockayne syndrome complementation group B associated with xeroderma pigmentosum phenotype. Hum Genet 1996a;97:176-9. PMID 8566949
54: Itoh T, Shiomi T, Shiomi N, et al. Rodent complementation group 8 (ERCC8) corresponds to Cockayne syndrome complementation group A. Mutat Res 1996b;362(2):167-74. PMID 8596535
55: Kajitani GS, Tomaz MA, Leandro GDS, et al. Altered pathways in Cockayne syndrome: involvement of MAPK, PI3K-Akt, extracellular matrix, inflammation, and neuronal signaling. DNA Repair (Amst) 2025;152:103861. PMID 40570619
56: Karikkineth AC, Scheibye-Knudsen M, Fivenson E, Croteau DL, Bohr VA. Cockayne syndrome: clinical features, model systems and pathways. Ageing Res Rev 2017;33:3-17. PMID 27507608
57: Khobta A, Sarmini L. Transcription-coupled nucleotide excision repair: a faster solution or the only option? Biomolecules 2025;15(7):1026. PMID 40723898
58: Khorrami M, Khorram E, Tabatabaiefar MA, et al. A truncating variant in the ERCC6 gene with three different phenotypes: significant effects of modifier genes. Genet Res (Camb) 2025;2025:7396691. PMID 41459025
59: Kleijer WJ, Laugel V, Berneburg M, et al. Incidence of DNA repair deficiency disorders in western Europe: xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. DNA Repair 2008;7(5):744-50. PMID 18329345
60: Kleijer WJ, van der Sterre ML, Garritsen VH, Raams A, Jaspers NG. Prenatal diagnosis of the Cockayne syndrome: survey of 15 years experience. Prenat Diagn 2006;26(10):980-4. PMID 16941719
61: Knoch J, Kamenisch Y, Kubisch C, Berneburg M. Rare hereditary diseases with defects in DNA-repair. Eur J Dermatol 2012;22(4):443-55. PMID 22436139
62: Kobaisi F, Fayyad N, Rezvani HR, et al. Signaling pathways, chemical and biological modulators of nucleotide excision repair: the faithful shield against UV genotoxicity. Oxid Med Cell Longev 2019;2019:4654206. PMID 31485292
63: Koob M, Laugel V, Durand M, et al. Neuroimaging in Cockayne syndrome. AJNR Am J Neuroradiol 2010;31(9):1623-30. PMID 20522568
64: Koob M, Rousseau F, Laugel V, et al. Cockayne syndrome: a diffusion tensor imaging and volumetric study. Br J Radiol 2016;89(1067):20151033. PMID 27643390
65: Kostova M, Banerjee A. Treatment outcomes of cochlear implantation in pediatric patients with Cockayne syndrome type I: a case series. J Surg Case Rep 2024;2024(5):rjae346. PMID 38803843
66: Kubota M, Ohta S, Ando A, et al. Nationwide survey of CS in Japan: incidence, clinical course and prognosis. Pediatr Int 2015;57(3):339-47. PMID 25851792
67: Laugel V. Cockayne syndrome: the expanding clinical and mutational spectrum. Mech Ageing Dev 2013;134(5-6):161-70. PMID 23428416
68: Laugel V, Dalloz C, Durand M, et al. Mutation update for the CSB/ERCC6 and CSA/ERCC8 genes involved in Cockayne syndrome. Hum Mutat 2010;31(2):113-26. PMID 19894250
69: Laugel V, Dalloz C, Tobias ES, et al. Cerebro-oculo-facio-skeletal syndrome: three additional cases with CSB mutations, new diagnostic criteria and an approach to investigation. J Med Genet 2008;45(9):564-71. PMID 18628313
70: Laverty DJ, Tomar R, Erlich S, Stone MP, Nagel ZD. The aflatoxin B1-induced formamidopyrimidine adduct is repaired by transcription-coupled nucleotide excision repair in human cells. NAR Cancer 2025;7(3):zcaf030. PMID 40918649
71: Lehmann AR. Three complementation groups in Cockayne syndrome. Mutat Res 1982;106:347-56. PMID 6185841
72: Lehmann AR, Thompson AF, Harcourt SA, Stefanini M, Norris PG. Cockayne's syndrome: correlation of clinical features with cellular sensitivity of RNA synthesis to UV irradiation. J Med Genet 1993;30:679-82. PMID 7692050
73: Le May N, Courraud J, Boujelbène I, et al. Clinical and molecular overlap between nucleotide excision repair (NER) disorders and DYRK1A haploinsufficiency syndrome. Front Neurosci 2025;19:1554093. PMID 40206408
74: Lerner LK, Moreno NC, Rocha CRR, et al. XPD/ERCC2 mutations interfere in cellular responses to oxidative stress. Mutagenesis 2019;34(4):341-54. PMID 31348825
75: Liakos A, Ntakou-Zamplara KZ, Angelova N, et al. Cockayne syndrome B protein is implicated in transcription and associated chromatin dynamics in homeostatic and genotoxic conditions. Aging Cell 2025;24(1):e14341. PMID 39370748
76: Liang F, Li B, Xu Y, et al. Identification and characterization of Necdin as a target for the Cockayne syndrome B protein in promoting neuronal differentiation and maintenance. Pharmacol Res 2023;187:106637. PMID 36586641
77: Low GKM, Ng GY, Zeegers D, et al. Protective role of Cockayne syndrome B (CSB) protein in maintaining genome integrity in human cells under oxidative stress. Mutat Res Genet Toxicol Environ Mutagen 2025;907:503887. PMID 41167909
78: Macdonald WB, Fitch KD, Lewis IC. Cockayne's syndrome: an heredo-familial disorder of growth and development. Pediatrics 1960;25:997-1007. PMID 14419337
79: Mayne LV, Lehmann AR. Failure of RNA synthesis to recover after UV irradiation: an early defect in cells from individuals with Cockayne’s syndrome and xeroderma pigmentosum. Cancer Res 1982;42(4):1473-8. PMID 6174225
80: Moriwaki S. Cockayne syndrome. [Article in Japanese] Brain Nerve 2019;71(4):390-3. PMID 30988227
81: Motojima T, Sugita K, Omata T, Fujii K. [Clinical examination of renal function in Cockayne syndrome]. No To Hattatsu 2014;46(4):311-4. PMID 25154231
82: Muftuoglu M, Sharma S, Thorslund T, et al. Cockayne syndrome group B protein has novel strand annealing and exchange activities. Nucleic Acids Res 2006;34(1):295-304. PMID 16410611
83: Nakazawa Y, Yamashita S, Lehmann AR, Ogi T. A semi-automated non-radioactive system for measuring recovery of RNA synthesis and unscheduled DNA synthesis using ethynyluracil derivatives. DNA Repair (Amst) 2010;9:506-16. PMID 20171149
84: Natale V. A comprehensive description of the severity groups in Cockayne syndrome. Am J Med Genet A 2011;155A(5):1081-95. PMID 21480477
85: Nance MA, Berry SA. Cockayne syndrome: review of 140 cases. Am J Med Genet 1992;42:68-84. PMID 1308368
86: Neilan EG, Delgado MR, Donovan MA, et al. Response of motor complications in Cockayne syndrome to carbidopa-levodopa. Arch Neurol 2008;65(8):1117-21. PMID 18695064
87: Neill CA, Dingwall MM. A syndrome resembling progeria: a review of two cases. Arch Dis Child 1950;25:213-21. PMID 14783428
88: Okur MN, Mao B, Kimura R, et al. Short-term NAD+ supplementation prevents hearing loss in mouse models of Cockayne syndrome. NPJ Aging Mech Dis 2020;6:1. PMID 31934345
89: Ovaert C, Cano A, Chabrol B. Aortic dilatation in Cockayne syndrome. Am J Med Genet 2007;143A(21):2604-6. PMID 17935247
90: Padmalayam P, Balan P, Sapkal R. Cockayne syndrome: role of genetic counseling. J Ayub Med Coll Abbottabad 2015;27(3):711-3. PMID 26721046
91: Pascucci B, Fragale A, Marabitti V, et al. CSA and CSB play a role in the response to DNA breaks. Oncotarget 2018;9(14):11581-91. PMID 29545921
92: Pasquier L, Laugel V, Lazaro L, et al. Wide clinical variability among 13 new Cockayne syndrome cases confirmed by biochemical assays. Arch Dis Child 2006;91(2):178-82. PMID 16428367
93: Pekhale K, Tiwari V, Hussain M, et al. Cockayne syndrome mice reflect human kidney disease and are defective in de novo NAD biosynthesis. Cell Death Differ 2025;32(11):2126-45. PMID 40374849
94: Pines A, Dijk M, Makowski M, et al. TRiC controls transcription resumption after UV damage by regulating CS protein A. Nat Commun 2018;9(1):1040. PMID 29531219
95: Proietti-De-Santis L, Balzerano A, Prantera G. CSB: an emerging actionable target for cancer therapy. Trends Cancer 2018;4(3):172-5. PMID 29506668
96: Raghavendran S, Brown KA, Buu N. Perioperative management of patients with Cockayne syndrome: recognition of accelerated aging with growth arrest. Paediatr Anaesth 2008;18(4):360-1. PMID 18315666
97: Rajamani G, Stafki SA, Daugherty AL, et al. Cognitive decline and other late-stage neurologic complications in Cockayne syndrome. Neurol Clin Pract 2024;14(4):e200309. PMID 38808024
98: Rapin I, Weidenheim K, Lindenbaum Y, et al. Cockayne syndrome in adults: review with clinical and pathologic study of a new case. J Child Neurol 2006;21(11):991-1006. PMID 17092472
99: Rawlinson SC, Webster VJ. Spinal anaesthesia for caesarean section in a patient with Cockayne syndrome. Int J Obstet Anesth 2003;12(4):297-9. PMID 15321464
100: Reid-Bayliss KS, Arron ST, Loeb LA, Bezrookove V, Cleaver JE. Why Cockayne syndrome patients do not get cancer despite their DNA repair deficiency. Proc Natl Acad Sci U S A 2016;113(36):10151-6. PMID 27543334
101: Ribeiro VB, Faria LTRA, Machado RL, Barcellos BM, Resende MAC, Videira RLR. Anesthesia for a cesarean section on a pregnant patient with Cockayne syndrome: case report. Rev Bras Anestesiol 2020;70(1):51-4. PMID 32173062
102: Roddan R, Schaich MA, Nathan WJ, et al. Molecular basis for CSB stimulation of the SNM1A DNA repair nuclease. Res Sq [Preprint] 2025. PMID 41333433
103: Salari M, Rezaei K, Asadi S, Etemadifar M. A case of ERCC6-related Cockayne syndrome presenting with levodopa-responsive tremor syndrome. Mov Disord Clin Pract 2023;10(12):1818-20. PMID 38094643
104: Sartorelli J, Travaglini L, Macchiaiolo M, et al. Spectrum of ERCC6-related Cockayne syndrome (type B): from mild to severe forms. Genes (Basel) 2024;15(4):508. PMID 38674442
105: Scheibye-Knudsen M. Neurodegeneration in accelerated aging. Dan Med J 2016;63(11). PMID 27808039
106: Schmickel RD, Chu EH, Trosko JE, Chang CC. Cockayne syndrome: a cellular sensitivity to ultraviolet light. Pediatrics 1977;60(2):135-9. PMID 887325
107: Shi Y, Diao Y, Li Q, Wang J. Unusual blood pressure response to local anesthetic in a patient with rare Cockayne syndrome undergoing dental surgery under general anesthesia. Paediatr Anaesth 2025;35(10):874-5. PMID 40698918
108: Smits MG, Gabreels FJ, Renier WO, et al. Peripheral and central myelinopathy in Cockayne's syndrome. Report of 3 siblings. Neuropediatrics 1982;13:161-7. PMID 7133337
109: Sonmez FM, Celep F, Uqur SA, Tolun A. Severe form of Cockayne syndrome with varying clinical presentation and no photosensitivity in a family. J Child Neurol 2006;21(4):333-7. PMID 16900932
110: Spitz MA, Severac F, Obringer C, et al. Diagnostic and severity scores for Cockayne syndrome. Orphanet J Rare Dis 2021;16(1):63. PMID 33536051
111: Spoden AM, McGrattan KE, Kang PB. Swallowing and communication in Cockayne syndrome: clinical characteristics and management. Am J Med Genet A 2026. [Epub ahead of print] PMID 41730799
112: Stafki SA, Turner J, Littel HR, et al. The spectrum of MORC2-related disorders: a potential link to Cockayne syndrome. Pediatr Neurol 2023;141:79-86. PMID 36791574
113: Stern-Delfils A, Spitz MA, Durand M, et al. Renal disease in Cockayne syndrome. Eur J Med Genet 2020;63(1):103612. PMID 30630117
114: Tanaka K, Kawai K, Kumahara Y, Ikenaga M, Okada Y. Genetic complementation groups in Cockayne syndrome. Somatic Cell Genet 1981;7(4):445-55. PMID 7280930
115: Theil AF, Häckes D, Lans H. TFIIH central activity in nucleotide excision repair to prevent disease. DNA Repair (Amst) 2023;132:103568. PMID 37977600
116: Theil AF, Hoeijmakers JH. Expanding the landscape of nucleotide excision repair disorders: from discovery to therapy. J Clin Invest 2025;135(22):e199822. PMID 41243966
117: Thorbinson C, Penn A, Nicola P, et al. Embryonal sarcoma of the liver in a girl with Cockayne syndrome. Clin Genet 2022;101(3):375-6. PMID 34878179
118: Tinsa F, Bellalah M, Brini I, et al. Infantile onset of Cockayne syndrome without photosensitivity in a Tunisian girl. Tunis Med 2009;87(12):877-9. PMID 20209858
119: Traboulsi EI, De Becker I, Maumanee IH. Ocular findings in Cockayne syndrome. Am J Ophthalmol 1992;114:579-83. PMID 1443019
120: Troelstra C, Hesen W, Bootsma D, Hoeijmakers JH. Structure and expression of the excision repair gene ERCC6, involved in the human disorder Cockayne's syndrome group B. Nucleic Acids Res 1993;21(3):419-26. PMID 8382798
121: Troelstra C, Odijk LH, de Wit J, et al. Molecular cloning of the human DNA excision repair gene ERCC-6. Mol Cell Biol 1990;10(11):5806-13. PMID 2172786
122: Troelstra C, van Gool A, de Wit J, Vermeulen W, Bootsma D, Hoeijmakers JHJ. ERCC6, a member of a subfamily of putative helicases, is involved in Cockayne’s syndrome and preferential repair of active genes. Cell 1992;71(6):939-53. PMID 1339317
123: Tsukamoto M, Hitosugi T, Yokoyama T. Discrepancy between electroencephalography and hemodynamics in a patient with Cockayne syndrome during general anesthesia. J Clin Anesth 2016;35:424-6. PMID 27871568
124: van Hoffen A, Natarajan AT, Mayne LV, van Zeeland AA, Mullenders LH, Venema J. Deficient repair of the transcribed strand of active in Cockayne’s syndrome cells. Nucleic Acids Res 1993;21(25):5890-5. PMID 8290349
125: van Sluis M, Gonzalo-Hansen C, Li Q, Lans H, Wang D, Marteijn JA. Mechanisms of transcription-coupled repair and DNA damage surveillance in health and disease. Nat Rev Mol Cell Biol 2026;27(3):234-51. PMID 41254380
126: Van Wyhe RD, Emery CV, Williamson RA. Cochlear implantation in pediatric patients with Cockayne syndrome. Int J Pediatr Otorhinolaryngol 2018;106:64-7. PMID 29447894
127: Venema J, Mullenders LH, Natarajan AT, van Zeeland AA, Mayne LV. The genetic defect in Cockayne syndrome is associated with a defect in repair of UV-induced DNA damage in transcriptionally active DNA. Proc Natl Acad Sci U S A 1990;87(12):4707–11. PMID 2352945
128: Vessoni AT, Herai RH, Karpiak JV, et al. Cockayne syndrome-derived neurons display reduced synapse density and altered neural network synchrony. Hum Mol Genet 2016;25(7):1271-80. PMID 26755826
129: Vos A, Gabreels-Festen A, Joosten E, Gabreels F, Renier W, Mullaart R. The neuropathy of Cockayne syndrome. Acta Neuropathol (Berl) 1983;61:153-6. PMID 6314729
130: Wang S, Min Z, Ji Q, et al. Rescue of premature aging defects in Cockayne syndrome stem cells by CRISPR/Cas9-mediated gene correction. Protein Cell 2020;11(1):1-22. PMID 31037510
131: Wilson BT, Hughes J. Joining the hidden revolution in rare diseases: working with family support groups. Arch Dis Child 2020;105(2):107-8. PMID 31196911
132: Zayoud K, Chikhaoui A, Kraoua I, et al. Immunity in the progeroid model of Cockayne syndrome: biomarkers of pathological aging. Cells 2024;13(5):402. PMID 38474366
133: Zhang D, Hartmann M, Cao Z, et al. Cockayne syndrome mutation in XPG activates the integrated stress response. Hum Genet 2026;145(1):15. PMID 41563504
134: Zhang X, Xu J, Hu J, et al. Cockayne syndrome linked to elevated R-loops induced by stalled RNA polymerase II during transcription elongation. Nat Commun 2024;15(1):6031. PMID 39019869

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Arushi Gahlot Saini MD DM MNAMS

Dr. Saini of Postgraduate Institute of Medical Education and Research, Chandigarh, India, has no relevant financial relationships to disclose.
See Profile

Editor

Ganeshwaran H Mochida MD PhD

Dr. Mochida of Boston Children's Hospital and Harvard Medical School has no relevant financial relationships to disclose.
See Profile

Former Authors

Gerald V Raymond MD
Tarakad S Ramachandran MD
Joseph R Siebert PhD

Patient Profile

Age range of presentation: 0 month to 18 years
Sex preponderance: male=female
Heredity: heredity typical

heredity may be a factor

autosomal recessive
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Cockayne syndrome: Q87.11
ICD-11: Syndromes with premature ageing appearance as a major feature: LD2B
OMIM: Cockayne syndrome type A: #216400

Cockayne syndrome type B: #133450

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Cockayne syndrome

Associated Disorders

Cataracts
Deafness
Dwarfism
Leukodystrophy
Lowry syndrome
- Mental retardation
- Optic atrophy
- Peripheral neuropathy
- Xeroderma pigmentosum

Differential Diagnosis

xeroderma pigmentosum
DeSanctis-Cacchione syndrome
Pelizaeus-Merzbacher disease
Hutchinson-Gilford syndrome

Also Relevant

Adrenoleukodystrophy
Cerebro-oculo-facio-skeletal syndrome
Idiopathic basal ganglia calcification
Intellectual disability
Leukodystrophies
- Nondominant hereditary ataxias
- Pelizaeus-Merzbacher disease

Cockayne syndrome …

Cockayne syndrome

Cite this article

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Agents and circumstances to avoid

Special considerations

Pregnancy

Anesthesia

Malignancy

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

GM2 gangliosidoses

Levacetylleucine

Hyperargininemia

HHH syndrome

Ornithine transcarbamylase deficiency

Carbamoyl phosphate synthetase 1 deficiency

Citrullinemias types 1 and 2

N-acetylglutamate synthase deficiency

Cockayne syndrome

Cite this article

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Agents and circumstances to avoid

Special considerations

Pregnancy

Anesthesia

Malignancy

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

GM2 gangliosidoses

Levacetylleucine

Hyperargininemia

HHH syndrome

Ornithine transcarbamylase deficiency

Carbamoyl phosphate synthetase 1 deficiency

Citrullinemias types 1 and 2

N-acetylglutamate synthase deficiency

This is an article preview.
Start a Free Account
to access the full version.